Shares keep trading as Annovis Bio gets a new NYSE “below criteria” mark
Annovis Bio (NYSE: ANVS) received a notice from the NYSE stating it is no longer compliant with listing standards due to low market capitalization. The company has 45 days to submit a plan to regain compliance within 9 months. Trading continues under the 'ANVS.BC' symbol, indicating below-criteria status.
How this was made
The 30-second read
Why it matters
The compliance notice introduces immediate risk of delisting, which can depress share price and affect liquidity. Investors will watch the company's remediation plan and any potential reverse split or OTC migration.
Market read
The notice is a primary corporate action for ANVS, likely prompting short‑term price pressure and heightened volatility.
What to watch
Potential for a reverse split or move to an over‑the‑counter market could mitigate delisting impact.
Background
Annovis Bio (NYSE: ANVS) is a Phase 3 biotech developing oral therapies for neurodegenerative diseases. The NYSE notice cites a 30‑day average market cap below the required threshold.
Ticker impact
Annovis Bio received a NYSE notice that its market cap fell below listing standards, triggering a potential delisting risk.
likely pressure as investors price in delisting risk and potential loss of NYSE listing
A compliance notice is a material corporate action that can quickly affect liquidity and valuation.
Market effects
May raise scrutiny on other small-cap biotech firms with marginal market caps.
Limited to U.S. exchange-listed microcaps; no broader regional effect.
Low; relevance confined to investors in ANVS and similar biotech listings.
Counterpoint
If the company successfully submits a compliance plan, the stock could rebound on relief rally.
Key entities
- companyAnnovis Bio, Inc.
Phase 3 clinical-stage biotech listed on NYSE under ticker ANVS.
- exchangeNew York Stock Exchange
Issuer of the compliance notice to ANVS.
